Abbvie Inc: (NYSE: ABBV)

$43.04

-0.50 (-1.15%)

Volume 3,659,877

Jun 19 04:02 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		43.01 - 43.83
	
		52wk Low - High
		32.51 - 48.00
	
		Previous Close
		43.54
	
		Avg. Volume
		4,790,299
	
		Industry
		LARGE CAP PHARMA
	
		Market Cap
		68.96 B
	
		Div - Yield
		1.60 - 3.67
	
		Beta
		0.05
	
		P/E (F1)
		13.91
	
		Current Year Est.
		3.13
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		175 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/3/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            13.91
                        
                            PEG Ratio
                            2.12
                        
                            Current Year Est.
                            3.13
                        
                            Current Quarter Estimate
                            0.79
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            07-26-2013
                        
                            EPS Last Year
                            3.47
                        
                            Expected Earnings Growth
                            6.57%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie aims to help patients' live healthier lives and collaborate on sustainable healthcare solutions.   
Full ABBV Company Report

 Snapshot on ABBV

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ABBV Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.79	0.77	3.13	3.23
Number of Estimates	6	5	9	7
Low Estimate	0.78	0.76	3.10	3.15
High Estimate	0.80	0.78	3.17	NA
Year Ago EPS	0.80	1.01	3.35	3.13
EPS Growth	-1.04%	-23.56%	-6.60%	3.14%

More ABBV Estimates

Average Earnings Estimates for ABBV

EPS Growth for ABBV

Industry Analysis

Name	Symbol	Previous Close
ABBVIE INC	ABBV	43.54
NOVO-NORDISK AS	NVO	161.87
ABBOTT LABS	ABT	37.51
ALLERGAN INC	AGN	101.49
ASTRAZENECA PLC	AZN	50.98
BRISTOL-MYERS	BMY	46.85
GLAXOSMITHKLINE	GSK	52.47
JOHNSON & JOHNS	JNJ	86.36
LILLY ELI & CO	LLY	52.35
MERCK & CO INC	MRK	47.75

Sector:Medical>> Industry:LARGE CAP PHARMA

COMPARE TICKER vs. Its Peers

Zacks Commentary

Data on BMY/ AbbVie's elotuzumab

Jun 17, 2013

Abbott Progresses with Absorb in Japan

Jun 14, 2013

New Data on UCB's Cimzia

Jun 14, 2013

Positive Data on Incyte/LLY's Baricitinib

Jun 14, 2013

Encouraging Data from Bristol-Myers

Jun 13, 2013

Label Expansion for Roche's RoActemra

Jun 12, 2013

Pipeline Progress at Roche

Jun 10, 2013

Abbott Labs' HPV Test in Canada

May 31, 2013

More ABBV Zacks Commentary

Financials

EPS TTM	3.47
Sales	18,380
Net Income	5,360
Price/Earnings	12.55
Price/Book	23.31
Price/Cash Flow	15.28
Price/Sales	3.72

More ABBV Financials

News

Medtronic Saga: Corrupt Science, Belated Warning - YCharts

Jun 18, 2013

AbbVie Issues Prelim. Results from Phase I Study of ABT-199/GDC-0199 for High-Risk CLL - Benzinga

Jun 17, 2013

AbbVie Presents Preliminary Results from Phase I Study of Investigational Oncology Compound ABT-199/GDC-0199 in Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) at European Hematology Association Annual Meeting - Pr Newswire

Jun 17, 2013

Abbott Progresses with Absorb in Japan - Zacks.Com

Jun 15, 2013

Bristol-Myers Squibb, AbbVie Announce Progression-Free Survival Data from Phase 2 Multiple Myeloma Study - Benzinga

Jun 15, 2013

A Peek Into The Market Before The Trading Starts - Benzinga

Jun 13, 2013

AbbVie Announces Positive Results from Concerto Trial - Benzinga

Jun 13, 2013

AbbVie Presents First Study Assessing the Role of Predefined Doses of Methotrexate When Used in Combination with HUMIRA(R) (adalimumab) for Rheumatoid Arthritis - Pr Newswire Europe

Jun 13, 2013

See All News Stories on ABBV

Broker Recommendations

Current ABR	2.14
ABR (Last Week)	2.14
# of recs in ABR	11
Average Target Price	43.67
Industry Rank by ABR	175 out of 265
Rank in Industry	2 out of 15

More ABBV Broker Recommendations

Day Low - High	43.01 - 43.83
52wk Low - High	32.51 - 48.00
Previous Close	43.54
Avg. Volume	4,790,299
Industry	LARGE CAP PHARMA
Market Cap	68.96 B
Div - Yield	1.60 - 3.67
Beta	0.05
P/E (F1)	13.91
Current Year Est.	3.13
Quarterly Earnings ESP	NA

P/E (F1)	13.91
PEG Ratio	2.12
Current Year Est.	3.13
Current Quarter Estimate	0.79
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	07-26-2013
EPS Last Year	3.47
Expected Earnings Growth	6.57%

Username: Password:

Remember me [?]

Abbvie Inc: (NYSE: ABBV)

$43.04

-0.50 (-1.15%)

Volume 3,659,877

Jun 19 04:02 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:LARGE CAP PHARMA

Zacks Commentary

Financials

News

Broker Recommendations